SCHEMBL3540684

SCHEMBL3540684

CN1CCN(c2ccc3[nH]c(-c4cccc5c(-c6nc7ccccc7[nH]6)n[nH]c45)nc3c2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 12/20 0.66
FLT1 P17948 7/20 0.66
KDR P35968 6/20 0.52
PDGFRB P09619 3/20 0.52
ACHE P22303 1/20 0.47
ABL1 P00519 1/20 0.47
RET P07949 2/20 0.46
CDK2 P24941 2/20 0.46
ERBB2 P04626 1/20 0.46
CDK1 P06493 1/20 0.46
CDK4 P11802 1/20 0.46
CCNA2 P20248 1/20 0.46
CCND1 P24385 1/20 0.46
CCND3 P30281 1/20 0.46
PDPK1 O15530 1/20 0.45
PDGFRA P16234 1/20 0.45
FGFR2 P21802 1/20 0.45
FGFR4 P22455 1/20 0.45
FGFR3 P22607 1/20 0.45
FLT3 P36888 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3535306 0.94 FGFR1 (0.75) FGFR1FLT1KDRPDGFRBABL1
SCHEMBL3543818 0.90 FGFR1 (0.53) FGFR1FLT1KDRPDGFRBACHE
SCHEMBL3537422 0.86 FGFR1 (0.49) FGFR1FLT1KDRPDGFRBABL1
SCHEMBL3539547 0.85 FGFR1 (0.61) FGFR1FLT1KDRPDGFRBRET
SCHEMBL3537757 0.85 FGFR1 (0.61) FGFR1FLT1KDRPDGFRBABL1
SCHEMBL3540367 0.84 FGFR1 (0.60) FGFR1FLT1KDRPDGFRBACHE
SCHEMBL3535690 0.84 FGFR1 (0.59) FGFR1FLT1KDRPDGFRBRET
SCHEMBL3539129 0.84 FGFR1 (0.59) FGFR1FLT1KDRABL1CDK2
SCHEMBL3536819 0.83 FGFR1 (0.71) FGFR1FLT1KDRPDGFRBACHE
SCHEMBL3542673 0.82 FGFR1 (0.70) FGFR1FLT1KDRCDK2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885KDR 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.